Nascent Biotech Inc. (NBIO)

[RNsidersbuying]

They've revised the previous need for $26M to needing $10 - $15M in the recent Q...

NEED FOR ADDITIONAL FINANCING:

Our current capital needs are estimated to be approximately $10-15 million. This will take us through Phase II clinical trials which is scheduled to begin in 2022 subject to the completion of phase 1 and FDA approval to proceed to phase 2.

https://www.otcmarkets.com/filing/html?id=15155687&guid=oJp1kFJoKOdkS3h

But at clinicaltrials.gov, I read clearly that Phase 1 results won't be fully known until 6/30/23???

https://www.clinicaltrials.gov/ct2/show/results/NCT04396717?term=pritumumab&draw=2&rank=1

Therefore, management remains flakily asleep-at-the-wheel at best...at worst...I shutter to think...that any one of us can get this at a lesser pps by simply applying a bit of patience, ya think?